Signal transduction-based strategies for the treatment of chronic myelogenous leukemia

Molecular Medicine Today

Volumn 2, Issue 12, 1996, Pages 503-509

  Senechal, Kristen ^b   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN;

ANIMAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; HUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; SIGNAL TRANSDUCTION;

EID: 0030332822     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)81454-2     Document Type: Review

References (43)

1. Kurzrock, R., Gutterman, J.U. and Talpaz, M. (1988) The molecular genetics of Philadelphia chromosome positive leukemias, New Engl. J. Med. 319, 990-998
2. Mackinnon, S. and Goldman, J.M. (1987) Bone marrow transplants for CML, Baillières Clin. Haematol. 1, 1055-1076
3. Goldman, J.M. et al. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion, Ann. Intern. Med. 108, 806-814
4. Bar, B.M. et al. (1993) Donor leukocyte infusions for chronic myeloid leukemia relapse after allogenic bone marrow transplantation, J. Clin. Oncol. 11, 513-519
5. Drobyski, W.R. et al. (1993) Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogenic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose, Blood 82, 3210-3218
6. Chen, W. et al. (1992) T-cell immunity to the joining region of p210 BCR-ABL protein, Proc. Natl. Acad. Sci. U. S. A. 89, 1468-1472
7. 2 as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia, New Engl. J. Med. 330, 820-825
8. 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia, Blood 87, 3883-3891
9. Sawyers, C.L. (1992) The bcr-abl gene in chronic myelogenous leukaemia, Cancer Surv. 15, 37-51
10. Heisterkamp, N. et al. (1991) Acute leukemia in bcr/abl gene transgenic mice, Nature 344, 251-253
11. Daley, G.Q., van Etten, R.A. and Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science 247, 824-830
12. Pendergast, A.M. et al. (1993) BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein, Cell 75, 175-185
13. Kipreos, E.T. and Wang, J.Y. (1992) Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA, Science 256, 382-385
14. Schlessinger, J. (1994) SH2/SH3 signaling proteins, Curr. Opin. Genet. Dev. 4, 25-30
15. ten Hoeve, J. et al. (1994) Cellular interactions of CRKL, and SH2-SH3 adaptor protein, Cancer Res. 54, 2563-2567
16. Feller, S.M., Knudsen, B. and Hanafusa, H. (1995) Cellular proteins binding to the first Src homology 3 (SH3) domain of the proto-oncogene product c-Crk indicate Crk-specific signaling pathways, Oncogene 10, 1465-1473
17. Ribon, V., Hubbell, S., Herrera, R. and Saltiel, A.R. (1996) The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner, Mol. Cell. Biol. 16, 45-52
18. Welch, P.J. and Wang, J.Y.J. (1993) A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle, Cell 75, 779-790
19. Goga, A. et al. (1995) p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase, Oncogene 11, 791-799
20. Shi, Y., Alin, K. and Goff, S.P. (1995) Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity, Genes Dev. 9, 2583-2597
21. Dai, Z. and Pendergast, A.M. (1995) Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity, Genes Dev. 9, 2569-2582
22. Sawyers, C.L., McLaughlin, J. and Witte, O.N. (1995) Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene, J. Exp. Med. 181, 307-313
23. Goga, A. et al. (1995) Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene, Cell 82, 981-988
24. Kaborowski, J.H.S., Allen, P.B. and Wiedemann, L.M. (1994) Temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells, EMBO J. 13, 5887-5895
25. Raitano, A.B., Halpern, J.R., Hambuch, T.M. and Sawyers, C.L. (1995) The bcr-abl leukemia oncogene activates Jun kinase and requires Jun for transformation, Proc. Natl. Acad. Sci. U. S. A. 92, 11746-11750
26. Shuai, K. et al. (1996) Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia, Oncogene 13, 247-254
27. Carlesso, N., Frank, D.A. and Griffin, J.D. (1996) Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl, J. Exp. Med. 183, 811-820
28. Ihle, J.N. and Kerr, I.M. (1995) Jaks and Stats in signaling by the cytokine receptor superfamily, Trends Genet. 11, 69-74
29. Kanwar, V.S., Witthuhn, B., Campana, D. and Ihle, J.N. (1996) Lack of constitutive activation of Janus kinases and signal transduction and activation of transcription factors in Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood 87, 4911-4912
30. Gishizky, M.L., Cortez, D. and Pendergast, A.M. (1995) Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation, Proc. Natl. Acad. Sci. U. S. A. 92, 10889-10893
31. Gibbs, J.B., Oliff, A. and Kohl, N.E. (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic, Cell 77, 175-178
32. Sawyers, C.L., Callahan, W. and Witte, O.N. (1992) Dominant negative myc blocks transformation by ABL oncogenes, Cell 70, 901-910
33. Szczylik, C. et al. (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides, Science 253, 562-565
34. Vaerman, J.L. et al. (1995) BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of nonantisense mechanism, Blood 86, 3891-3896
35. Skorski, T. et al. (1995) Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells, Blood 86, 726-736
36. de Fabritis, P. et al (1995) In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation, Leukemia 9, 662-664
37. Ratajczak, M.Z. et al. (1992) Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides, Blood 79, 1956-1961
38. Shah, N.P., Witte, O.N. and Denny, C.T. (1991) Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines, Mol. Cell. Biol. 11, 1854-1860
39. Verfaillie, C.M., Miller, W.J., Boylan, K. and McGlave, P.B. (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression, Blood 79, 1003-1010
40. Gale, R.P. et al (1994) Identical-twin bone marrow transplants for leukemia, Ann. Intern. Med. 120, 646-652
41. Buchduner, E.J. et al. (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative, Cancer Res. 56, 100-104
42. Kaur, G. et al. (1994) Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia, Anti-Cancer Drugs 5, 213-222
43. Druker, B.J. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat. Med. 2, 561-566